| Drug Name: | Disopyramide ((3737-09-5)) |
|---|---|
| PubChem ID: | 3114 |
| SMILES: | |
| InchiKey: | UVTNFZQICZKOEM-UHFFFAOYSA-N |
| Therapeutic Category: |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Azithromycin (83905-01-5) | Ventricular Fibrillation | Additive | Not fully established. An in vitro study using human liver microsomes indicated that azithromycin inhibits the metabolism (mono-N-dealkylation) of disopyramide which, in vivo, would be expected to reduce its loss from the body and increase its serum levels | Potentially fatal interaction between azithromycin and disopyramide |
| Clarithromycin (81103-11-9) | Hypoglycaemia | Additive | Not fully established. The increased serum levels of disopyramide can result in adverse effects such as QT prolongation and torsade de pointes, and may result in enhanced insulin secretion and hypoglycaemia | Life-threatening interaction between clarithromycin and disopyramide |
| Clarithromycin (81103-11-9) | Torsade De Pointes | Additive | Not fully established. The increased serum levels of disopyramide can result in adverse effects such as QT prolongation and torsade de pointes, and may result in enhanced insulin secretion and hypoglycaemia | Life-threatening interaction between clarithromycin and disopyramide |
| Erythromycin (114-07-8) | Arrhythmia | Additive | Not fully established. An in vitro study using human liver microsomes indicated that erythromycin inhibits the metabolism (mono-N-dealkylation) of disopyramide which, in vivo, would be expected to reduce its loss from the body and increase its serum levels. | Potentially fatal interaction between erythromycin and disopyramide |
| Phenytoin (57-41-0) | Loss Of Arrhythmic Control | Antagonistic | Phenytoin, which is a known enzyme-inducer, increases the metabolism of the disopyramide by the liver. Although, the major metabolite (N-dealkyldisopyramide) also possesses antiarrhythmic activity the net effect is a reduction in arrhythmic control | Effect of phenytoin on serum disopyramide concentrations |
| Practolol (6673-35-4) | Bradycardia | Additive | Not understood. Both disopyramide and the beta blockers can depress the contractility and conductivity of the heart muscle | Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates |
| Sotalol (3930-20-9) | Asystole | Additive | Not understood. Both disopyramide and the beta blockers can depress the contractility and conductivity of the heart muscle | A case report Sotalol-disopyramide caused asystole |
| verapamil (52-53-9) | Hypotension | Additive | Not established | Collapse after oral administration of disopyramide |
| Amiodarone (1951-25-3) | Pr Prolongation | Additive | Amiodarone is a class III antiarrhythmic and can prolong the QT interval. Disopyramide is a class Ia antiarrhythmic and also prolongs the QT interval. Their additive effects can result in the development of torsade de pointes arrhythmias | Harmful interactions of amiodarone and class I anti-arrhythmia agents |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category
| Toxicity | Source |
|---|